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tor, emergency department (ED), or “other,” as well as the number of CD-related
hospital admission days. Unit costs were assigned to each type of health care
resource using national non-Medicare 2011 reimbursement rates. Hospitalization
cost was estimated using the HCUP.net mean daily cost of inpatient stay (principal
diagnosis 333.83). Cost of an ED visit was estimated by the mean paid amount for
ED visit (principal diagnosis 333.83) using commercial claims data. RESULTS: Base-
line data were available for 786 participants at time of analysis. The mean age was
57.7 years, and the majority (76%) were female. The mean (SD) number of visits to
a primary care providerwas 1.4 (2.1), 1.9 (1.9) for neurologist, 0.7 (1.8) for physiatrist,
1.8 (3.8) for physical/occupational therapy, 0.2 (0.9) for neurosurgeon, 1.3 (3.1) for
alternative care provider, 1.1 (3) for chiropractor, and 3.2 (2.7) for “other.” Partici-
pants reported amean(SD) of 0.2(0.9) visits to the ED and 0.1(0.6) hospital admission
days. The mean total cost of CD over 6 months was $1,255.80 (range $0-$63,320.20;
median $639.80). The largest single cost driver was the number of hospital admis-
sion days. CONCLUSIONS: The economic impact of CD-related health care re-
source use should not be overlooked when assessing disease burden.
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OBJECTIVES: The economic burden of Multiple Sclerosis (MS) on society and the
individuals concerned is not known. Documenting such costs is essential for sev-
eral reasons: costs of illness is a key factor of optimal diseasemanagement policies,
knowledge of cost is useful for allocating research anddevelopment. The aimof our
study as the first pharmacoeconomic investigation in Iran was to estimate the
costs of multiple sclerosis according to severity of disease.METHODS: Total, direct
and indirect costs were compared in 160 patients divided into three groups cate-
gorized by disease severity: stage I Expanded Disability Status Scale (EDSS 2.5),
stage II (EDSS 3- 4.5) and stage III (EDSS 5).The majority of these patients (94%)
developed relapsing- remitting MS.A minority of the patients (0.2-4 %) developed
secondary progressive and primary progressive MS. Cost evaluation was per-
formed from the societal perspective and covered the one-year period. The study
was carried out at the Division of Neurology at GhaemHospital andMS association
in Mashhad in northeast of Iran and was approved by the local ethics committee.
RESULTS: The mean total cost/patient for one year was estimated at $27,095,
$27,997and $31,662 for stage I, II and III, respectively. Both direct and indirect costs
increased with MS progression. For indirect cost the main item was productivity
loss. Themean extramedicine (treatments forMS symptoms and adverse effects of
medications) cost/patient for one year was calculated at $19,036. CONCLUSIONS:
This study confirms that MS represents a high economic burden to patients and
society, with direct costs greatly exceeding indirect costs. As costs increase with
disease progression, treatment efforts should focus on patients in the early stages
of MS. Disease support system that monitors a variety of common progressive
signs for the MS individuals is a key element of a management program as well.
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OBJECTIVES: Seizure control through antiepileptic drugs (AEDs) is integral to treat-
ment of Lennox-Gastaut syndrome (LGS). Although six AEDs are approved for LGS
(clobazammost recently, October 2011), no standard treatment paradigm has been
established. Understanding the economic burden associated with LGS is critical to
developing such guidance. The objective of this study was to examine health care
resource utilization and costs for patients with LGS.METHODS:Medical and phar-
macy claims data (1/1/2007–9/30/2010) from a large US managed health care plan
affiliated with OptumInsight were analyzed. Study patients were those with evi-
dence of LGS based on 2medical claims (30 days apart) with diagnosis (ICD-9-CM)
of generalized, nonconvulsive (or convulsive) epilepsy. Evidence of developmental
diagnoses and 12 months of continuous health plan enrollment following initial
epilepsy diagnosis were required. Health care resource utilization and costs were
examined during a 12-month follow-up period and computed separately as all-
cause, epilepsy-related (i.e., any epilepsy care), or related to seizure-attributable
events (e.g., lacerations, fractures). RESULTS: A total of 1,948 patients with evi-
dence of LGS were identified; demographics were consistent with published sur-
veys. Mean counts of epilepsy-related health care visits at 12 months were 10.73
(all-cause: 33.97) for ambulatory visits and 0.75 (all-cause: 0.86) for inpatient ad-
missions. Mean epilepsy-related health care cost was $29,911 (all-cause: $44,797),
of which the greatest components were inpatient costs (epilepsy-related: $18,119;
all-cause: $19,590) and ambulatory costs (epilepsy-related: $5,515; all-cause: $11,907).
Meanmedical cost related to seizure-attributable eventswas$13,038.CONCLUSIONS:
A high economic burden was observed in this LGS sample, with frequent health
care visits and high costs attributable to epilepsy care. Nearly one-third of total
medical costs were associated with seizure-attributable events, highlighting the
need for effective seizure control. These results will be useful for understanding
the budgetary impact and cost effectiveness of AED therapy in LGS treatment.
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OBJECTIVES: The majority of epileptic patients manage their condition with anti-
epileptic drugs (AEDs) to prevent seizures. Despite being adherent to AEDs, some
patients fail to have adequate seizure control; therefore, they have refractory epi-
lepsy. This study assessed the health care costs and resource utilization of epilepsy
patients with partial onset seizures (POS) who were refractory compared to non-
refractory patients.METHODS:Administrative claims from 2004-2008 in a US com-
mercially insured population were analyzed. Patients aged 18-64 years were se-
lected if they had medical claims with POS (ICD-9-CM codes: 345.4, 345.5). This
study used an operational definition of 3 different AED agents dispensed as refrac-
toriness. Patients were considered refractory from the year they received the third
AED and forward. Annual direct health care utilization and costs within each cal-
endar year among patients who were continuously enrolled were compared be-
tween refractory and non-refractory cohorts. RESULTS: The study identified 79,149
patients with POS (mean age 33 years; 54.8% female), and 8,714 (11%) patients
became refractory. In 2008, refractory patients were more likely to have a hospital
admission (27.2% vs. 16.9%; p0.001). Average annual health care costs for refrac-
tory patients were significantly higher than non-refractory patients ($33,613 vs.
$19,085; p0.001), as well as by settings for inpatient ($11,780 vs. $6,076; p0.001),
outpatient ($12,677 vs. $8,125; p0.001) and pharmacy costs ($5,280 vs. $2,256;
(p0.001). Close to half of total costs were attributable to POS-related services.
Similar trends were observed when assessing POS-related costs and utilization.
The differences were consistent across calendar years examined. CONCLUSIONS:
The findings from this study suggest refractoriness in epilepsy patients with POS is
associated with high economic burden from the health insurer’s perspective. Re-
fractory patients incurred 76%more healthcare costs than non-refractory patients.
Improving seizure control and reducing the economic burden of refractory epilepsy
remain important unmet medical needs in this population.
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OBJECTIVES: This study estimated health care resource utilization (HCRU) and
medical costs in both pediatric and adult Medicaid populations, comparing epilep-
sy-related costs with overall costs. METHODS: A retrospective analysis was con-
ducted using Thomson Reuters’ Medicaid claims data from 13 states (2005-2009).
Epilepsy patients were identified through ICD-9 code 345.xx and 780.39. Annual
HCRU and medical costs (in 2009 dollars) in adult (18 years) and pediatric pa-
tients (2-17 years) were estimated separately. HCRU was considered as epilepsy-
related if it was associated with ICD-9 code of 345.xx or 780.39, or was an anti-
epileptic drug. RESULTS: A total of 75,111 patients were identified with epilepsy,
with 31,484 pediatric (mean age 8.8 years) and 43,627 adult (mean age 40.4 years).
Annually, a pediatric patient with epilepsy incurred 0.23 hospital admissions (0.13
epilepsy-related), 1.31 ER visits (0.38 epilepsy-related), 6.12 physician office visits
(1.25 epilepsy-related), 3.25 outpatient hospital visits (0.91 epilepsy-related), 27.17
other outpatient visits (1.62 epilepsy-related), 22.3 prescriptions (3.96 epilepsy-re-
lated). Among adult patients, average HCRU was 0.90 hospital admissions (0.43
epilepsy-related), 3.52 ER visits (0.66 epilepsy-related), 10.26 physician office visits
(1.62 epilepsy-related), 7.44 outpatient hospital visits (1.07 epilepsy-related), 58.69
other outpatient visits (2.65 epilepsy-related), 71.43 prescriptions (10.1 epilepsy-
related). Direct medical costs per patient were $10,669 (18.4% epilepsy-related) for
a pediatric patient and $29,886 (17.7% epilepsy-related) for an adult patient. Overall
directmedical costs associated with active epilepsy in the identifiedMedicaid pop-
ulation were $293 million ($62 million for pediatric and $231 million for adult).
CONCLUSIONS: Non-epilepsy related HCRU and direct medical costs dominated
HCRU and direct medical costs in Medicaid patients with epilepsy, indicating that
substantial comorbidities are associated with epilepsy patients in the Medicaid
population. Adult patients had higher HCRU and direct medical costs compared to
pediatric patients, which may be related to likely differences in the types of epi-
lepsy experienced by children and adults.
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OBJECTIVES: Based on the work of Sicras-Mainar et al. 2011, evaluating real world
data on the resource consumption of patients treated with pregabalin and gabap-
entin for neuropatic pain, an adaptation to the Brazilian public health care system
was carried in order to compare both strategies. METHODS: A cost-minimization
study was designed considering the length of treatment, daily dose strengths dis-
tributions, hospitalization days, medical visits, physiotherapy sessions and other
concomitant medications used. Frequencies and resource use was obtained from
the aforementioned study, and prices were retrieved from national databases
(Banco de Preços em Saúde and SIGTAP - Sistema de Gerenciamento da Tabela de
Procedimentos, Medicamentos e OPM do SUS). To best represent the values for the
not-normal distribution of length of treatment frequencies reported in the study, a
Monte Carlo simulation using 10.000 iterationswas carried considering a triangular
distribution. The timehorizonwas defined as 1 year. Valueswere expressed in 2011
USD. RESULTS:The overall costs ofmedications compared in this study per patient
were 332.74 and 291.20 USD for pregabalin and gabapentin, respectively. Health
care utilization costs were 89.12 and 128.76 USD for pregabalin and gabapentin
treated patients respectively. Other concomitant medication costs were 56.29 and
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